Ianalumab with TPO-RA for immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary ITP or Evans syndrome (a condition with low platelets and autoimmune hemolytic anemia).
- If you have ITP: You have had a platelet count below 100 and are currently taking or starting a TPO-RA medicine (like eltrombopag or romiplostim) for at least 2 weeks before starting the study drug.
- If you have Evans syndrome: You have active low platelets and warm antibody hemolytic anemia, and have not responded well to steroids.
- You are 18 years or older.
- You have not had more than 4 prior treatments for ITP (for ITP patients).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two medicines (ianalumab and eltrombopag) for children with a blood condition called ITP (low platelets causing bruising and bleeding) who haven't improved with steroids. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This study tests a sequence of two medicines that help raise platelet counts in people with severe ITP. The first is given as an injection, and the second is a pill, and they are given after standard steroid treatment. The goal is to see if this approach can improve platelet levels safely.
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.